BioPharma Dive· Gwendolyn Wu·· 3 hours agoPickScore64
Protein degrader specialist Lycia prices $318M IPO
In brief
Lycia Therapeutics priced a $318 million IPO, selling more shares than expected. Its stock, ticker LYCA, began trading on the Nasdaq on Friday.
Why it matters
The article gives Lycia's IPO size, three pipeline programs' progress, and LYTAC mechanism arguments, enabling comparison with other early-stage programs in the field.
Source: BioPharma Dive · biopharmadive.com